scholarly journals Faculty Opinions recommendation of Efficacy of follitropin-alpha versus human menopausal gonadotropin for male patients with congenital hypogonadotropic hypogonadism.

2021 ◽  
Author(s):  
Roberto Maggi
Keyword(s):  
Hypogonadotropic Hypogonadism ◽  
Human Menopausal Gonadotropin ◽  
Congenital Hypogonadotropic Hypogonadism ◽  
Male Patients

scholarly journals The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men

2018 ◽  
Vol 13 (1) ◽  
pp. 155798831881828 ◽  
Author(s):  
Luyao Zhang ◽  
Ke Cai ◽  
Yu Wang ◽  
Wen Ji ◽  
Zhen Cheng ◽  
...  
Keyword(s):  
Hypogonadotropic Hypogonadism ◽  
Serum Testosterone ◽  
High Serum ◽  
Serum Testosterone Level ◽  
Common Side Effect ◽  
Human Menopausal Gonadotropin ◽  
Luteinizing Hormone Level ◽  
Contributing Factors ◽  
Congenital Hypogonadotropic Hypogonadism ◽  
Serum Luteinizing Hormone

The objective of this study was to compare the effect of pulsatile gonadorelin pump (PGP) and cyclical gonadotropin (human chorionic gonadotropin [HCG]/human menopausal gonadotropin [HMG]) therapy (CGT) on spermatogenesis in congenital hypogonadotropic hypogonadism (CHH) men. Twenty-eight azoospermic CHH males were included in this nonrandomized study. Ten received PGP and 18 received CGT. The primary endpoint was the earliest time spermatogenesis occurred during 24 months of treatment. Spermatogenesis time was significant earlier in the PGP group than the CGT group (median of 6 and 14 months, respectively, χ2 = 6.711, p = .01). Spermatogenesis occurred in 90% of the PGP group and 83.3% of the CGT group and showed statistically insignificant difference in the superiority analysis and the no-inferior test. Contributing factors significant for spermatogenesis were previous HCG/or testosterone treatment and the peak serum luteinizing hormone level of triptorelin stimulation test at baseline. Although testis volume and penile length increased significantly from baseline, the differences between the two therapies were not significant. There was a tendency for high serum testosterone level, associated with more facial acne and breast tenderness in the CGT group. Skin allergic erythema scleroma was a common side effect of the PGP. In summary, PGP resulted in earlier spermatogenesis and more desirable testosterone levels than CGT.

Gonadotropins for testicular descent in cryptorchid congenital hypogonadotropic hypogonadism males beyond infancy

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Shreya Sharma ◽  
Ravikumar Shah ◽  
Virendra Patil ◽  
Anurag R. Lila ◽  
Vijaya Sarathi ◽  
...  
Keyword(s):  
Semen Analysis ◽  
Hypogonadotropic Hypogonadism ◽  
Sperm Concentration ◽  
Inhibin B ◽  
Testicular Descent ◽  
Total Testosterone ◽  
Human Menopausal Gonadotropin ◽  
Beneficial Effects ◽  
Congenital Hypogonadotropic Hypogonadism

Abstract Objectives To study the effect of combined gonadotropin therapy (CGT) on testicular descent ± spermatogenesis in congenital hypogonadotropic hypogonadism (CHH) patients with cryptorchidism beyond infancy. Methods This retrospective cohort study included CHH patients with cryptorchidism [bilateral (n=5) or unilateral (n=1)] treated with CGT for testicular descent ± pubertal induction. All participants were treated with CGT [human menopausal gonadotropin (hMG) and human chorionic gonadotropin (hCG)] with hMG pretreatment in three and monitored for changes in testicular volume (TV), serum total testosterone (T), serum inhibin-B, and sperm concentration. Results Complete testicular descent to the scrotal position was achieved in 5/6 patients (10/11 testes) after 4.7 ± 1.6 months of treatment. There was 44 ± 18%, 97.5% (IQR: 44–195), 10-fold (IQR: 3–19.6), and two-fold (IQR: 1.7–9.3) increase in stretched penile length, ultrasound measured TV, T level, and serum inhibin-B from baseline, respectively. In two pediatric cases, testicular descent occurred with isolated hMG therapy. At the last follow up (median: 23.5, IQR: 10.5–38.7 months), all the descended testes remained in scrotal position. In four pubertal/postpubertal age patients, continuous CGT (18–60 months) yielded T and inhibin-B levels of 16.64 ± 1.46 nmol/l and 106 ± 32.6 pg/mL, respectively. All the three patients with available semen analysis had sperm concentration of ≥5 million/mL and one of them achieved paternity. Conclusions A trial of CGT before orchiopexy may be considered in CHH males with cryptorchidism even beyond the narrow age-window of infancy. CGT may also have beneficial effects on future spermatogenesis and fertility outcomes in these patients.

Health-related quality of life in male patients with congenital hypogonadotropic hypogonadism

2015 ◽  
Vol 83 (1) ◽  
pp. 141-143 ◽  
Author(s):  
Tero Varimo ◽  
Matti Hero ◽  
Eeva-Maria Laitinen ◽  
Harri Sintonen ◽  
Taneli Raivio
Keyword(s):  
Quality Of Life ◽  
Hypogonadotropic Hypogonadism ◽  
Health Related Quality ◽  
Congenital Hypogonadotropic Hypogonadism ◽  
Related Quality ◽  
Health Related ◽  
Male Patients

scholarly journals Predictors of reproductive and non-reproductive outcomes of gonadotropin mediated pubertal induction in male patients with congenital hypogonadotropic hypogonadism (CHH)

2021 ◽  
Author(s):  
B. Cangiano ◽  
G. Goggi ◽  
S. Federici ◽  
C. Bresesti ◽  
L. Cotellessa ◽  
...  
Keyword(s):  
Genetic Background ◽  
Semen Analysis ◽  
Hypogonadotropic Hypogonadism ◽  
Bone Age ◽  
Reproductive Outcomes ◽  
Targeted Next Generation Sequencing ◽  
Congenital Hypogonadotropic Hypogonadism ◽  
Gonadotropin Stimulation ◽  
Complete Form ◽  
Male Patients

Abstract Purpose To investigate predictors of testicular response and non-reproductive outcomes (height, body proportions) after gonadotropin-induced puberty in congenital hypogonadotropic hypogonadism (CHH). Design A retrospective analysis of the puberty induction in CHH male patients, undergoing an off-label administration of combined gonadotropin (FSH and hCG). Methods Clinical and hormonal evaluations before and during gonadotropin stimulation in 19 CHH patients genotyped by Targeted Next Generation Sequencing for CHH genes; 16 patients underwent also semen analysis after gonadotropins. Results A lesser increase in testicular volume after 24 months of induction was significantly associated with: (I) cryptorchidism; (II) a positive genetic background; (III) a complete form of CHH. We found no significant correlation with the cumulative dose of hCG administered in 24 months. We found no association with the results of semen analyses, probably due to the low numerosity. Measures of body disproportion (eunuchoid habitus and difference between adult and target height: deltaSDSth), were significantly related to the: (I) age at the beginning of puberty induction; (II) duration of growth during the induction; (III) initial bone age. The duration of growth during induction was associated with previous testosterone priming and to partial forms of CHH. Conclusions This study shows that a strong genetic background and cryptorchidism, as indicators of a complete GnRH deficiency since intrauterine life, are negative predictors of testicular response to gonadotropin stimulation in CHH. Body disproportion is associated with a delay in treatment and duration of growth during the induction, which is apparently inversely related to previous androgenization.

Sign in / Sign up

Export Citation Format

Share Document